MALT1 accelerates proatherogenic vascular smooth muscle cell growth, invasion and synthetic phenotype switching via nuclear factor‑κB signaling‑dependent way

Zheng,Haiying; Bai,Ligang

doi:10.3892/etm.2023.12036

MALT1 accelerates proatherogenic vascular smooth muscle cell growth, invasion and synthetic phenotype switching via nuclear factor‑κB signaling‑dependent way

Authors:
- Haiying Zheng
- Ligang Bai
View Affiliations

Affiliations: Department of Cardiovascular, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, P.R. China, Department of Urology Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, P.R. China
Published online on: May 22, 2023 https://doi.org/10.3892/etm.2023.12036
Article Number: 337
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mucosa‑associated lymphoid tissue lymphoma translocation protein 1 (MALT1) modulates T helper cell differentiation and nuclear factor‑κB (NF‑κB) pathway‑mediated inflammation and potentially regulates lipid metabolism, which are all critical factors involved in atherosclerosis. The present study aimed to investigate the effect of MALT1 on the cellular functions of proatherogenic vascular smooth muscle cells (VSMCs). Therefore, to establish a human proatherogenic VSMC model, VSMCs were treated with different doses of oxidized low‑density lipoprotein (oxLDL). Subsequently, the effect of MALT1 overexpression or knockdown in proatherogenic VSMCs treated with or without NF‑κB activator was also explored. The results showed that treatment of proatherogenic VSMCs with oxLDL significantly elevated the mRNA and protein expression levels of MALT1 in a dose‑dependent manner. Furthermore, MALT1 overexpression enhanced cell viability, invasion and phenotype switching and reduced apoptosis in proatherogenic VSMCs. However, MALT1 knockdown exerted the opposite effect on the above cellular functions. Additionally, the results revealed that MALT1 could positively regulate the NF‑κB pathway in proatherogenic VSMCs. Moreover, treatment of proatherogenic VSMCs with NF‑κB activator not only exacerbated the dysregulation of cellular functions, but also hampered the effect of MALT1 knockdown on attenuating cell growth, invasion and synthetic phenotype switching, thus suggesting that NF‑κB was essential for the regulation of MALT1‑triggered functions in proatherogenic VSMCs. In conclusion, the current study suggested that MALT1 could exacerbate cell viability, mobility and synthetic phenotype switching of proatherogenic VSMCs in a NF‑κB signaling‑dependent manner. Therefore, MALT1 could be considered as a potential therapeutic target for atherosclerosis.

View Figures

View References

1	Bjorkegren JLM and Lusis AJ: Atherosclerosis: Recent developments. Cell. 185:1630–1645. 2022.PubMed/NCBI View Article : Google Scholar
2	Dawson LP, Lum M, Nerleker N, Nicholls SJ and Layland J: Coronary atherosclerotic plaque regression: JACC State-of-the-Art review. J Am Coll Cardiol. 79:66–82. 2022.PubMed/NCBI View Article : Google Scholar
3	Mendelson SJ and Prabhakaran S: Diagnosis and management of transient ischemic attack and acute ischemic stroke: A review. JAMA. 325:1088–1098. 2021.PubMed/NCBI View Article : Google Scholar
4	Seiffge DJ, Wilson D and Wu TY: Administering thrombolysis for acute ischemic stroke in patients taking direct oral anticoagulants: To treat or how to treat. JAMA Neurol. 78:515–516. 2021.PubMed/NCBI View Article : Google Scholar
5	Xiong Y, Wakhloo AK and Fisher M: Advances in acute ischemic stroke therapy. Circ Res. 130:1230–1251. 2022.PubMed/NCBI View Article : Google Scholar
6	Bhatt DL, Lopes RD and Harrington RA: Diagnosis and treatment of acute coronary syndromes: A review. JAMA. 327:662–675. 2022.PubMed/NCBI View Article : Google Scholar
7	Gaudino M and Taggart DP: Percutaneous coronary intervention vs coronary artery bypass grafting: A surgical perspective. JAMA Cardiol. 4:505–506. 2019.PubMed/NCBI View Article : Google Scholar
8	Miano JM, Fisher EA and Majesky MW: Fate and state of vascular smooth muscle cells in atherosclerosis. Circulation. 143:2110–2116. 2021.PubMed/NCBI View Article : Google Scholar
9	Liu YX, Yuan PZ, Wu JH and Hu B: Lipid accumulation and novel insight into vascular smooth muscle cells in atherosclerosis. J Mol Med (Berl). 99:1511–1526. 2021.PubMed/NCBI View Article : Google Scholar
10	Zhang F, Guo X, Xia Y and Mao L: An update on the phenotypic switching of vascular smooth muscle cells in the pathogenesis of atherosclerosis. Cell Mol Life Sci. 79(6)2021.PubMed/NCBI View Article : Google Scholar
11	Bennett MR, Sinha S and Owens GK: Vascular smooth muscle cells in atherosclerosis. Circ Res. 118:692–702. 2016.PubMed/NCBI View Article : Google Scholar
12	DeVore SB and Khurana Hershey GK: The role of the CBM complex in allergic inflammation and disease. J Allergy Clin Immunol. 150:1011–1030. 2022.PubMed/NCBI View Article : Google Scholar
13	Qi T, Luo Y, Cui W, Zhou Y, Ma X, Wang D, Tian X and Wang Q: Crosstalk between the CBM complex/NF-kappaB and MAPK/P27 signaling pathways of regulatory T cells contributes to the tumor microenvironment. Front Cell Dev Biol. 10(911811)2022.PubMed/NCBI View Article : Google Scholar
14	McAllister-Lucas LM, Jin X, Gu S, Siu K, McDonnell S, Ruland J, Delekta PC, Van Beek M and Lucas PC: The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis. J Biol Chem. 285:25880–25884. 2010.PubMed/NCBI View Article : Google Scholar
15	Wu X, Zheng X, Cheng J, Zhang K and Ma C: LncRNA TUG1 regulates proliferation and apoptosis by regulating miR-148b/IGF2 axis in ox-LDL-stimulated VSMC and HUVEC. Life Sci. 243(117287)2020.PubMed/NCBI View Article : Google Scholar
16	Wang W, Chen L, Shang C, Jin Z, Yao F, Bai L, Wang R, Zhao S and Liu E: miR-145 inhibits the proliferation and migration of vascular smooth muscle cells by regulating autophagy. J Cell Mol Med. 24:6658–6669. 2020.PubMed/NCBI View Article : Google Scholar
17	Snow JB, Norton CE, Sands MA, Weise-Cross L, Yan S, Herbert LM, Sheak JR, Gonzalez Bosc LV, Walker BR, Kanagy NL, et al: Intermittent hypoxia augments pulmonary vasoconstrictor reactivity through PKCβ/Mitochondrial oxidant signaling. Am J Respir Cell Mol Biol. 62:732–746. 2020.PubMed/NCBI View Article : Google Scholar
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar
19	Meng H, Ruan J, Yan Z, Chen Y, Liu J, Li X and Meng F: new progress in early diagnosis of atherosclerosis. Int J Mol Sci. 23(8939)2022.PubMed/NCBI View Article : Google Scholar
20	Fan J and Watanabe T: Atherosclerosis: Known and unknown. Pathol Int. 72:151–160. 2022.PubMed/NCBI View Article : Google Scholar
21	Vekic J, Zeljkovic A, Cicero AFG, Janez A, Stoian AP, Sonmez A and Rizzo M: Atherosclerosis development and progression: The role of atherogenic small, dense LDL. Medicina (Kaunas). 58(299)2022.PubMed/NCBI View Article : Google Scholar
22	Lin P, Ji HH, Li YJ and Guo SD: Macrophage plasticity and atherosclerosis therapy. Front Mol Biosci. 8(679797)2021.PubMed/NCBI View Article : Google Scholar
23	Wang D, Zhou Z and Yuan L: Polydatin reverses oxidation low lipoprotein (oxLDL)-induced apoptosis of human umbilical vein endothelial cells via regulating the miR-26a-5p/BID axis. Eur J Histochem. 66(3505)2022.PubMed/NCBI View Article : Google Scholar
24	Wang K, Bai X, Mei L, Miao Y and Jin F: CircRNA_0050486 promotes cell apoptosis and inflammation by targeting miR-1270 in atherosclerosis. Ann Transl Med. 10(905)2022.PubMed/NCBI View Article : Google Scholar
25	Al Mansouri M, Patel PA, Chamberlain J and Francis S: OxLDL induces IL-1β release from human EC and VSMC via different caspase-1 dependent mechanisms. Vasc Biol. 4:11–18. 2022.PubMed/NCBI View Article : Google Scholar
26	Chen X, Zhang X, Lan L, Xu G, Li Y and Huang S: MALT1 positively correlates with Th1 cells, Th17 cells, and their secreted cytokines and also relates to disease risk, severity, and prognosis of acute ischemic stroke. J Clin Lab Anal. 35(e23903)2021.PubMed/NCBI View Article : Google Scholar
27	Rhoads JP, Lukens JR, Wilhelm AJ, Moore JL, Mendez-Fernandez Y, Kanneganti TD and Major AS: Oxidized low-density lipoprotein immune complex priming of the Nlrp3 inflammasome involves TLR and FcγR cooperation and is dependent on CARD9. J Immunol. 198:2105–2114. 2017.PubMed/NCBI View Article : Google Scholar
28	Wang Q, Wang Y, Liu Q, Chu Y, Mi R, Jiang F, Zhao J, Hu K, Luo R, Feng Y, et al: MALT1 regulates Th2 and Th17 differentiation via NF-κB and JNK pathways, as well as correlates with disease activity and treatment outcome in rheumatoid arthritis. Front Immunol. 13(913830)2022.PubMed/NCBI View Article : Google Scholar
29	Wei S, Sun J, Li Y, Xu K, Wang M and Zhang Y: Losartan attenuates atherosclerosis in uremic mice by regulating Treg/Th17 balance via mediating PTEN/PI3K/Akt pathway. Nephron. 146:528–538. 2022.PubMed/NCBI View Article : Google Scholar
30	Madonna R and De Caterina R: Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease. Vascul Pharmacol. 57:41–47. 2012.PubMed/NCBI View Article : Google Scholar
31	Knies N, Alankus B, Weilemann A, Tzankov A, Brunner K, Ruff T, Kremer M, Keller UB, Lenz G and Ruland J: Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation. Proc Natl Acad Sci USA. 112:E7230–E7238. 2015.PubMed/NCBI View Article : Google Scholar
32	Wang Q, Wang Y and Xu D: Research progress on Th17 and T regulatory cells and their cytokines in regulating atherosclerosis. Front Cardiovasc Med. 9(929078)2022.PubMed/NCBI View Article : Google Scholar
33	Kaltschmidt B, Helweg LP, Greiner JFW and Kaltschmidt C: NF-κB in neurodegenerative diseases: Recent evidence from human genetics. Front Mol Neurosci. 15(954541)2022.PubMed/NCBI View Article : Google Scholar
34	Zhang T, Ma C, Zhang Z, Zhang H and Hu H: NF-κB signaling in inflammation and cancer. MedComm (2020). 2:618–653. 2021.PubMed/NCBI View Article : Google Scholar
35	Ding S, Liu J, Han X, Ding W, Liu Z, Zhu Y, Zhan W, Wan Y, Gai S, Hou J, et al: ICAM-1-related noncoding RNA accelerates atherosclerosis by amplifying NF-κB signaling. J Mol Cell Cardiol. 170:75–86. 2022.PubMed/NCBI View Article : Google Scholar
36	Zheng Y, Li Y, Ran X, Wang D, Zheng X, Zhang M, Yu B, Sun Y and Wu J: Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-κB/IL-6 signaling pathway. Cell Mol Life Sci. 79(311)2022.PubMed/NCBI View Article : Google Scholar
37	Liu C, Wu J, Jia H, Lu C, Liu J, Li Y and Guo M: Oncostatin M promotes the ox-LDL-induced activation of NLRP3 inflammasomes via the NF-κB pathway in THP-1 macrophages and promotes the progression of atherosclerosis. Ann Transl Med. 10(456)2022.PubMed/NCBI View Article : Google Scholar
38	Ruland J and Hartjes L: CARD-BCL-10-MALT1 signalling in protective and pathological immunity. Nat Rev Immunol. 19:118–134. 2019.PubMed/NCBI View Article : Google Scholar
39	Yeh CC, Wu JY, Lee GL, Wen HT, Lin P and Kuo CC: Vanadium derivative exposure promotes functional alterations of vsmcs and consequent atherosclerosis via ROS/p38/NF-κB-Mediated IL-6 production. Int J Mol Sci. 20(6115)2019.PubMed/NCBI View Article : Google Scholar